Page 18 - Read Online
P. 18

Tulotta et al. J Cancer Metastasis Treat 2019;5:74  I  http://dx.doi.org/10.20517/2394-4722.2019.022                          Page 3 of 11














































               Figure 1. CXCL12-induced signalling via CXCR4 and CXCR7. (A) CXCL12 binds to CXCR4, inducing Gα and Gβγ dissociation and
               activation of PI3K, MAPK, AC, and PLC signalling pathways. CXCL12 binding to CXCR4 activates β-Arrestin, leading to MAPK signalling
               pathway activation or receptor internalization. (B) CXCR4 can form homo- and hetero-dimers with CXCR7. (C) CXCL12 binding to CXCR7
               induces, via β-Arrestin, MAPK signalling activation, or CXCL12 scavenging, through receptor internalisation and recycling to the plasma
               membrane. CXCL12-mediated signalling plays a role in cell chemotaxis, migration, proliferation and survival. PI3K: phosphatidylinositide
               3-kinase; MAPK: mitogen-activated protein kinases; AC: adenyly cyclase; PLC: phospholipase C

                     [24]
                                     [25]
                                                   [26]
               (GBM) , Ewing sarcoma  and leukemia . Elevated CXCR4 levels result in increased cell proliferation,
               dedifferentiation, migration and metastatic spreading of tumour cells, cancer stem cell (CSC) maintenance
               and it has been associated with the development of tumour resistance towards conventional therapies,
                                           [27]
               leading to poor patient prognosis .
               CXCR4 is expressed by both cancer cells and surrounding stromal cells [Figure 2]. The recruitment of
               stromal cells expressing CXCR4 can be guided by the secretion of CXCL12 by cancer cells themselves
                                                         [28]
               or other stromal cells, such as MSCs and CAFs . Moreover, CXCL12 secreted by CAFs displays effects
                                                        [29]
               on tumour cells, enhancing invasive potential  and functioning as a protective shield against T cells,
                                                    [30]
               boosting immune escaping mechanisms . In this context, pharmacological inhibition of CXCR4,
               resulted in redistribution of CD3+ T cells within the “cancer cell nest”, as defined by the authors, causing
                                                                                      [31]
               reduced cancer cell growth and improved response to check-point inhibitors . CXCR4 is involved
               in leukocyte trafficking, hematopoietic stem progenitor cells homing and neutrophil retention in the
               bone marrow during homeostasis, inflammation, infection and cancer [12,32-35] . Infiltration of CXCR4hi
               neutrophils associates with faster tumour growth and angiogenesis in IFNβ deficient mice, injected with
                                        [36]
               melanoma and fibrosarcoma . CXCR4hi macrophages have been identified in CXCL12-enriched tumour
   13   14   15   16   17   18   19   20   21   22   23